President-Elect Trump to Pick Mehmet Oz to Head CMS
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Nov. 19, 2024 -- President-elect Donald Trump says he will nominate Mehmet Oz, M.D., to head the Centers for Medicare & Medicaid Services.
In a statement, Trump said that Oz will "work closely with Robert Kennedy Jr. to take on the illness industrial complex, and all the horrible chronic diseases left in its wake," The New York Times reported. Trump also remarked that Oz had "won nine Daytime Emmy Awards hosting 'The Dr. Oz Show,' where he taught millions of Americans how to make healthier lifestyle choices."
Oz, the son of Turkish immigrants, worked as a heart surgeon before helming a hugely successful daytime talk show, focused on health and medicine, from 2009 through 2022. He went on to lose a 2022 bid to represent Pennsylvania in the Senate to Democrat John Fetterman.
Oz emerged as a conservative firebrand during and after the pandemic, railing against policies he claimed "took away our freedom." During the pandemic, he was a vocal supporter of now-discredited COVID-19 "treatments" such as hydroxychloroquine and chloroquine.
Earlier in his career, Oz was forced to testify before Congress for promoting miracle weight-loss pills without any proof of efficacy.
In 2020, Oz penned an opinion column in Forbes in which he called for a form of universal health coverage in which any American not covered by Medicaid would be enrolled in a private Medicare Advantage plan. An "affordable 20 percent payroll tax" would pay for the coverage, he wrote.
The New York Times Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-21 00:00
Read more
- Global TB Cases Hit Record High, TB Becomes Top Infectious Disease Killer
- Florida Fails to Pass Amendment Legalizing Recreational Weed
- Women, Men on Kidney Dialysis Face Different Heart Risks
- Election Fears Are Compromising the Sleep Health of Americans
- Racial, Ethnic Differences Seen in Cleft Lip Surgery Repair
- Nipocalimab is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-to-Severe Sjögren’s Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions